Stanford University
Showing 131-140 of 825 Results
-
Nazish Sayed MD, PhD
Associate Professor (Research) of Surgery (Vascular Surgery)
Current Research and Scholarly InterestsThe Sayed Laboratory investigates how endothelial dysfunction contributes to cardiovascular disease and leverages human stem cell technologies to identify novel therapeutic strategies. Our research integrates patient-derived induced pluripotent stem cells (iPSCs), engineered cardiac tissues, organoids, human biospecimens, and multi-omic technologies to uncover mechanisms underlying inherited and acquired cardiovascular diseases.
A major focus of the laboratory is understanding endothelial–cardiomyocyte communication in cardiomyopathy. Using patient-specific iPSCs, human cardiac organoids, engineered heart tissues, spatial transcriptomics, and single-cell multi-omics, we study how endothelial dysfunction drives myocardial fibrosis, inflammation, and heart failure. Current efforts include investigations into LMNA-related dilated cardiomyopathy, endothelial-to-mesenchymal transition (EndoMT), and mechanisms of fibrotic remodeling.
A second major area of research is cardio-oncology. The laboratory develops human disease models to understand cardiovascular complications associated with cancer therapies, including tyrosine kinase inhibitors and immune checkpoint inhibitors. These studies have identified novel vascular mechanisms underlying treatment-related hypertension, cardiomyopathy, and heart failure.
The laboratory also investigates cardiovascular aging, toxic environmental exposures, rare vascular diseases, and regenerative medicine. By integrating human tissues, advanced stem cell models, genome engineering, spatial biology, and artificial intelligence–enabled multi-omic analyses, our goal is to develop precision therapeutic strategies that improve cardiovascular health and patient outcomes. -
Michael Scahill
Clinical Assistant Professor, Pediatrics - Neonatology
BioOn a trip to Mozambique while in med school here at Stanford, Dr Scahill saw the power of market interventions to transform healthcare. This led to his current focus on technology, data & AI. A veteran data scientist, his research trawls the oceans of data each patient generates for patterns to predict dangerous outcomes before they happen in Stanford's top level NICU, where he also still serves as a frontline clinician. Outside Stanford, he is the digital lead at Valley Children's hospital and advises health technology startups in Silicon Valley and beyond.
-
John Scandling
Professor of Medicine (Nephrology) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsTolerance induction in clinical kidney transplantation
-
Laura Schaefer
Assistant Professor of Earth and Planetary Sciences and, by courtesy, of Geophysics
Current Research and Scholarly Interestsearly Earth atmosphere; planetary differentiation; rocky exoplanet atmospheric chemistry; planetary interiors; atmosphere-interior exchange on Earth-like planets; planetary habitability; Venus atmospheric evolution; volcanic gases on Io and volatile loss
-
Lidia Schapira
Professor of Medicine (Oncology)
BioDr. Schapira is a medical oncologist with clinical expertise in the treatment of breast cancer. As the inaugural Director of Stanford's Cancer Survivorship Program, she has developed a thriving research and clinical program focused on optimizing health outcomes for people living with and beyond cancer. Dr. Schapira is interested in training future generations of physician-scientists as well as the broader community of practicing physicians through the design of innovative educational programs. Dr. Schapira's advocacy for people with cancer led to her appointment as Editor-in-Chief of the American Society of Clinical Oncology's website for the public,Cancer.Net, a position she held from 2015 until-2021. She served on the Board of Directors of the American Psychosocial Oncology Society and as Chair of the Psychosocial Interest Group of the Multinational Society for Supportive Care in Cancer. Dr. Schapira is particularily committed to reducing inequities in cancer outcomes and improve access to cancer care and cancer clinical trials. Dr. Schapira has published numerous manuscripts, lectures both nationally and internationally on issues of cancer survivorship and served as Associate Editor of the narrative section, Art of Oncology, for the Journal of Clinical Oncology from 2013 until 2023.
